Patents by Inventor Christina B. Madsen-Duggan

Christina B. Madsen-Duggan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INSULIN RECEPTOR PARTIAL AGONISTS
    Publication number: 20230310551
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: August 24, 2021
    Publication date: October 5, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Christina B. Madsen-Duggan, Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Ravi Nargund, Christopher R. Moyes, Dmitri A. Pissarnitski, Zhicai Shi, Zhicai Wu, Lin Yan, Yuping Zhu
  • Insulin receptor partial agonists
    Patent number: 10800827
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: October 13, 2020
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • INSULIN RECEPTOR PARTIAL AGONISTS
    Publication number: 20190092833
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: November 26, 2018
    Publication date: March 28, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Inhibitors of HIF prolyl hydroxylase
    Patent number: 10208060
    Abstract: The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: February 19, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiaqiang Cai, Alejandro Crespo, John Debenham, Xiaoxing Du, Ping Liu, Rongqiang Liu, Christina B. Madsen-Duggan, Weiguo Quan, Christopher Sinz, Liping Wang
  • Insulin receptor partial agonists
    Patent number: 10183981
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: January 22, 2019
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • INSULIN RECEPTOR PARTIAL AGONISTS
    Publication number: 20180291078
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: June 13, 2018
    Publication date: October 11, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Insulin receptor partial agonists
    Patent number: 10017556
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: July 10, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Inhibitors of HIF prolyl hydroxylase
    Patent number: 10000501
    Abstract: The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: June 19, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jiaqiang Cai, Vincent Colandrea, Alejandro Crespo, John Debenham, Xiaoxing Du, Deodialsingh Guiadeen, Ping Liu, Rongqiang Liu, Christina B. Madsen-Duggan, Joshua G. McCoy, Weiguo Quan, Christopher Sinz, Liping Wang
  • INSULIN RECEPTOR PARTIAL AGONISTS
    Publication number: 20170355743
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: November 19, 2015
    Publication date: December 14, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170313718
    Abstract: The present invention concerns compounds of formula I or a pharmaceutically acceptable salt thereof which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: September 23, 2015
    Publication date: November 2, 2017
    Applicants: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTD.
    Inventors: JIAQIANG CAI, ALEJANDRO CRESPO, JOHN DEBENHAM, XIAOXING DU, PING LIU, RONGQIANG LIU, CHRISTINA B. MADSEN-DUGGAN, WEIGUO QUAN, CHRISTOPHER SINZ, LIPING WANG
  • INHIBITORS OF HIF PROLYL HYDROXYLASE
    Publication number: 20170240555
    Abstract: The present invention concerns a compound of formula I or a pharmaceutically acceptable salt thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 24, 2017
    Applicants: MERCK SHARP & DOHME CORP., MSD R&D (CHINA) CO., LTD.
    Inventors: JIAQIANG CAI, VINCENT COLANDREA, ALEJANDRO CRESPO, JOHN DEBENHAM, XIAOXING DU, DEODIALSINGH GUIADEEN, PING LIU, RONGQIANG LIU, CHRISTINA B. MADSEN-DUGGAN, JOSHUA G. MCCOY, WEIGUO QUAN, CHRISTOPHER SINZ, LIPING WANG
  • INSULIN RECEPTOR PARTIAL AGONISTS
    Publication number: 20170107268
    Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
    Type: Application
    Filed: November 19, 2015
    Publication date: April 20, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
  • Prolylcarboxypeptidase inhibitors
    Patent number: 9006268
    Abstract: Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: April 14, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John S. Debenham, Jinlong Jiang, Christina B. Madsen-Duggan, Dong-Ming Shen
  • Tetrahydrothieno pyridines
    Patent number: 8445680
    Abstract: The present invention relates to tetrahydrothienopyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: May 21, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John S. Debenham, Jeffrey J. Hale, Christina B. Madsen-Duggan, Thomas F. Walsh
  • NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS
    Publication number: 20130090324
    Abstract: Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders.
    Type: Application
    Filed: June 6, 2011
    Publication date: April 11, 2013
    Inventors: John S. Debenham, Jinlong Jiang, Christina B. Madsen-Duggan, Dong-Ming Shen
  • Tetrahydro-1H-pyrrolo fused pyridones
    Patent number: 8372863
    Abstract: The present invention relates to tetrahydro-1H-pyrrolo fused pyridone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: February 12, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Matthew J. Clements, Vincent J. Colandrea, John S. Debenham, Jeffrey J. Hale, Christina B. Madsen-Duggan, Thomas F. Walsh
  • Substituted 4-hydroxypyrimidine-5-carboxamides
    Patent number: 8278304
    Abstract: The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: October 2, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Matthew J. Clements, John S. Debenham, Jeffrey J. Hale, Christina B. Madsen-Duggan, Thomas F. Walsh
  • Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
    Patent number: 7999107
    Abstract: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, Huntington's disease movement disorders, and schizophrenia.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: August 16, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John S. Debenham, Jeffrey J. Hale, Pei Huo, Christina B. Madsen-Duggan, Thomas F. Walsh, Lin Yan
  • TETRAHYDROTHIENO PYRIDINES
    Publication number: 20110009425
    Abstract: The present invention relates to tetrahydrothienopyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
    Type: Application
    Filed: February 11, 2009
    Publication date: January 13, 2011
    Inventors: John S. Debenham, Jeffrey J. Hale, Christina B. Madsen-Duggan, Thomas F. Walsh
  • TETRAHYDRO-1H-PYRROLO FUSED PYRIDONES
    Publication number: 20110009406
    Abstract: The present invention relates to tetrahydro-1H-pyrrolo fused pyridone compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.
    Type: Application
    Filed: February 11, 2009
    Publication date: January 13, 2011
    Inventors: Matthew J. Clements, Vincent J. Colandrea, John S. Debenham, Jeffrey J. Hale, Christina B. Madsen-Duggan, Thomas F. Walsh